ReviewFrontiers in pharmacology2023
Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications.
Tingting Fang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
13 papers cite it
this paperpooled itcites it